Singapore, March 13 -- Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, has successfully secured a$110 millionSeries E financing led by a private equity fund of Value Partners Group, one ofAsia'slargest independent asset management firms, with strong participation from industry- and technology-focused new investors, as well as continued support from global existing backers.

The funds raised in this round will be directed to advance Insilico's innovative drug pipeline and AI platform developments. On one side, resources will focus on refining AI models and algorithms, alongside updates and expansions to its state-of-the-artautomaticlab to further automate and streamline R&D process...